Glucosamine, a common over-the-counter joint supplement used by more than 40 million Americans, may be linked to faster progression of dementia in some older adults, according to new research. The findings raise questions about the safety of a product long marketed as a relatively benign aid for joint pain.
The preliminary study, published in Nature Metabolism, suggests that glucosamine use was associated with a higher risk that people with existing memory problems would deteriorate more quickly. Researchers stress that the findings show an association and do not prove that the supplement directly causes harm.
What the new research found
Scientists at the University of Florida analyzed electronic health records from more than 65,000 people, including around 41,000 with mild cognitive impairment and 24,000 with dementia. About 8% of this combined group had been taking glucosamine supplements.
Among people with mild cognitive impairment, glucosamine users had a 25% higher likelihood of progressing to dementia compared with non-users. Among patients already diagnosed with Alzheimer’s disease or related dementias, glucosamine use was associated with a 25% higher risk of death within five years.
Researchers caution that other factors, including overall health, mobility problems or additional medications, could partly explain the observed pattern. A randomized clinical trial would be needed to determine whether glucosamine itself is responsible for the differences in cognitive decline and mortality.
How glucosamine may affect the brain
Glucosamine is a naturally occurring, sugar-related molecule that the body uses to build and repair cartilage. It is widely taken by older adults for osteoarthritis and general joint discomfort, often for long periods without medical supervision.
The compound can cross the blood-brain barrier, but its effects on brain cells remain unclear. The new study focuses on how glucosamine could influence a process called glycosylation, in which sugar chains known as glycans are attached to proteins inside cells.
In brain tissue from people who died with Alzheimer’s disease, the Florida researchers found globally increased levels of glycan structures compared with healthy controls. The more advanced the Alzheimer’s pathology, the more of these added “sugar decorations” appeared in gray matter.
Under normal conditions, carefully regulated sugar tags help proteins fold correctly, reach the appropriate locations within cells and function as intended. In Alzheimer’s disease, this tagging system appears to become overactive, potentially contributing to protein misfolding and toxic buildup rather than protecting cells.
Links to metabolic dysfunction
Some scientists increasingly view Alzheimer’s disease as having major metabolic components, sometimes informally referring to it as “type 3 diabetes.” Within this framework, disrupted energy use and abnormal sugar processing in brain cells may contribute to disease progression.
The Florida researchers hypothesize that glucosamine could worsen problems in people whose brain metabolism is already impaired. By supplying additional building blocks for glycans, the supplement might contribute to the overactive sugar-tagging process observed in Alzheimer’s brains.
This could help explain why earlier observational studies suggested that glucosamine might reduce dementia risk among generally healthy adults, while the new analysis identifies a potential downside specifically among people with existing cognitive problems. The neurometabolic state of the brain may influence whether glucosamine is neutral, beneficial or harmful.
Evidence from animal experiments
To explore causality, researchers turned to mice genetically engineered to develop Alzheimer’s-like symptoms. When they blocked the enzyme responsible for producing sugar molecules similar to glucosamine, the animals’ dementia-related behaviors improved.
By contrast, when these Alzheimer’s-prone mice were given glucosamine, their memory deficits worsened. Healthy mice receiving the same supplement did not show clear cognitive changes, reinforcing the idea that glucosamine’s effects may depend on underlying brain vulnerability.
The animal findings support the human data but cannot fully reproduce the complexity of human dementia. Still, they point to hyperglycosylation, or excessive sugar tagging of proteins, as a potential new hallmark and therapeutic target in Alzheimer’s disease and related disorders.
Implications for patients and doctors
Experts emphasize that the findings should not trigger panic or immediate, universal discontinuation of glucosamine. Instead, they argue for more nuanced discussions of risks and benefits, particularly for older adults with mild cognitive impairment or diagnosed dementia.
Many people begin taking glucosamine based on anecdotal reports or marketing claims about improved knee and joint health. Evidence for its effectiveness in osteoarthritis is mixed, with some meta-analyses suggesting modest benefits and others finding little difference compared with placebo.
Given the new concerns, clinicians may want to review supplement use more carefully among patients experiencing memory problems. Researchers involved in the study say they now plan to follow dementia patients who stop taking glucosamine to determine whether their disease trajectory differs from that of people who continue using it.
In an accompanying commentary, biochemist Yasuhiko Kizuka, who was not involved in the research, argued that abnormal protein glycosylation may provide a new therapeutic avenue. Targeting this sugar-tagging system could, in theory, slow or modify Alzheimer’s progression if future studies confirm that it plays a central role.
For now, the study underscores a broader point: even supplements generally perceived as harmless can have complex biological effects, particularly in vulnerable populations. Patients are encouraged to discuss long-term supplement use with their physicians rather than assuming that “natural” automatically means safe.
